|
|
News Breaks | | | | January 18, 2013 | | 10:58 EDT |  | JNJ | Earnings Preview: Johnson & Johnson at five-year high ahead of Q4 report
Johnson & Johnson (JNJ) is scheduled to report Q4 results before the open on Tuesday January 22, with a conference call scheduled for 8:30 am ET. Johnson & Johnson engages in the research and development, manufacture, and sale of various products in the health care field worldwide... EXPECTATIONS: Analysts are looking for EPS of $1.17 on revenue of $17.67B, according to First Call. The consensus range for EPS is $1.13-$1.23 on revenue of $17.46B-$17.98B... LAST QUARTER: J&J reported Q3 EPS $1.25 against estimates of $1.21 on revenue of $17.1B against estimates of $16.95B. In its Q3 report, the company gave FY12 EPS guidance of $5.05-$5.10 compared to estimates of $5.06. J&J cited by Remicade, Prezista, Velcade as Q3 growth drivers but noted that Q3 sales were hurt by manufacturing suspension at Doxil/Caelyx supplier. During the Q3 earnings conference call CFO Dominic Caruso said U.S. healthcare utilization rates show early signs of stabilization and U.S. joint reconstruction volumes appear to have improved in the latest data but cautioned that although some positive signs can be seen, it is "still too early to signal any meaningful recovery"... STREET RESEARCH: In the last two months, analysts have been generally positive on J&J. On January 4, Deutsche Bank upgraded Johnson & Johnson to Buy from Hold, citing the company's diversification and expectations the company will see improving trends in 2013. The firm raised its price target for shares to $82 from $75. On December 10, Davenport upgraded the shares to Buy from Neutral with an $80 price target... PRICE ACTION: Shares of Johnson and Johnson are trading near a five-year high of ~$73. The shares rose from around $69 per share to $72.74 on Q3 earnings in October, and have since rallied approximately 5% to $72.94. | |
|
News For JNJ From The Last 14 Days Check below for free stories on JNJ the last two weeks. |
|
|
| May 21, 2013 | | 07:24 EDT |  | JNJ | Global Health Care to host a conference
 Subscribe for More Information | | | May 17, 2013 | | 06:19 EDT |  | JNJ | J&J to end sales of of metal-on-metal hip replacements, Bloomberg reports
Subscribe for More Information | | | May 15, 2013 | | 16:51 EDT |  | JNJ | FDA approves Simponi to treat ulcerative colitis
Subscribe for More Information | | | May 10, 2013 | | 11:48 EDT | | JNJ | Drugmakers to face pressure on U.S. prices, Reuters says
Subscribe for More Information | | | 06:16 EDT | | JNJ | Obesity surgery booming in India, Bloomberg reports
Subscribe for More Information | | | May 9, 2013 | | 17:09 EDT | | JNJ | Johnson & Johnson deal to settle sales practices probe stalls, WSJ reports
Johnson & Johnson's $2.2B settlement with the Justice Department related to its promotion of certain drugs is on hold as the company is looking to avoid language in the agreement that could make it vulnerable to private lawsuits, reports The Wall Street Journal, citing people familiar with the talks. Reference Link | | | 09:51 EDT | | JNJ | J&J unit says first patient enrolled in reMARQable study
Subscribe for More Information | | | May 8, 2013 | | 07:38 EDT | | JNJ | BofA/Merrill's medical tech analyst hold an analyst/industry conference call
Subscribe for More Information | |
|
|
|
|
|
|
